Kuznicki Law is investigating the proposed merger of Kintara Therapeutics, Inc. (the “Company”) (NasdaqCM: KTRA) and TuHURA Biosciences, Inc. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, and whether the merger is fair to Kintara shareholders.
Kintara Therapeutics, Inc. (NasdaqCM: KTRA) Loss Submission Form
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.